BASF ups Pronova bid


BASF has increased its offer for Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids, from €664 million (£530 million) to €684 million in an attempt to win over reluctant shareholders.

The company made its initial offer in November 2012 with the support of the board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Since then, the bid has been accepted by investors owning 70% of the issued shares. The new offer lasts until 18 January and will not be extended, BASF says.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements. It employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).

BASF strengthened its position in this growing market in May 2012 when it bought UK firm Equateq.


Related Content

BASF bids €664m for omega-3 company

22 November 2012 Business

news image

Pronova BioPharma makes pharmaceutical ingredients as well as nutritional supplements based in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Flowing rivers of mercury

7 January 2015 Feature

news image

Philip Ball investigates claims that the burial chamber of China’s first emperor contains rivers of shimmering mercury

Most Commented

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments

The big experiment

23 January 2015 Critical Point

news image

Plans to stop assessing school pupils’ practical work are the wrong solution to a genuine problem, says Mark Peplow